At the official opening ceremony of AbbVie Biologics Manufacturing Facility (Left to Right): Marc O'Donoghue, Site Director of AbbVie Operations Singapore; Dr Beh Swan Gin, Chairman, Singapore Economic Development Board; Mr. S Iswaran, Minister of Trade & Industry (Industry); Rick Gonzalez, Chairman of the Board and Chief Executive Officer of AbbVie; Azita Saleki-Gerhardt, Senior Vice President and President of AbbVie Operations and Daniella Ottini, Vice-President of Manufacturing Operations Biologics
AbbVie, a global research and development-based biopharmaceutical company, opened its Biologics Manufacturing Facility, expanding its capabilities to include biological products in addition to its existing small molecule active pharmaceutical ingredient (API) facility.
The combined facilities support the company's global manufacturing operations to address AbbVie's pipeline in the therapeutic areas of immunology and oncology.
AbbVie Global Manufacturing Facility, Singapore
"Today's milestone represents our dedication to providing life-changing treatments for patients. Just as we are focused on uncovering therapies to address unmet patient needs, equally important is enhancing our capabilities to ensure supply of these medicines for our patients," said Azita Saleki-Gerhardt, Ph.D., senior vice president, operations, AbbVie.
Located in Tuas Biomedical Park, this facility is expected to employ about 250 people across different roles such as supply chain management, technical operations and manufacturing.
"We are delighted that AbbVie has chosen Singapore as the location for the establishment of their first biologics manufacturing facility in Asia. AbbVie's latest investment is testament to Singapore's strong track record of high quality biopharmaceutical manufacturing. We continue to see strong growth in this industry sector, and EDB remains committed to invest in areas such as talent, technology and infrastructure to support this growth." said Ms. Ho Weng Si, Director, Biomedical Sciences, Singapore Economic Development Board (EDB). Mr Rick Gonzalez, chairman of the board and CEO of AbbVie added that the biologics manufacturing facility would not have been possible without the tremendous support from the Singapore Government and EDB.
The Singapore site is the only one in the AbbVie global manufacturing network to house both API and biologics manufacturing capabilities. The local API facility started operations for commercial supply earlier this year. Singapore joins 12 other sites across the US, Europe and Puerto Rico in AbbVie's global manufacturing network.